文献速递淋巴瘤造血干细胞移植与细胞治疗

抗CD25放射免疫联合BEAM自体造血干细胞移植预处理治疗霍奇金淋巴瘤

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

这项1期剂量递增试验评估了90Y-抗CD25(aTac)联合BEAM方案在22例高危复发难治性经典型霍奇金淋巴瘤患者中进行自体造血干细胞移植(AHCT)预处理的安全性和推荐2期剂量。未观察到剂量限制性毒性,推荐2期剂量为0.6 mCi/kg,5年无进展生存率和总生存率分别为68%和95%,非复发死亡率为0%。

要点

  • aTac-BEAM方案在高危复发难治性霍奇金淋巴瘤患者中耐受良好,未出现剂量限制性毒性。
  • 推荐2期剂量为0.6 mCi/kg,该剂量下心脏壁受照剂量不超过2500 cGy。
  • 22例可评估患者中,5年无进展生存率为68%,总生存率为95%,非复发死亡率为0%。

核心结论

  • aTac-BEAM自体造血干细胞移植预处理在高危复发难治性霍奇金淋巴瘤患者中安全可行。

研究设计与样本

  • 1期剂量递增试验,纳入25例高危复发难治性经典型霍奇金淋巴瘤患者,最终22例接受治疗性aTac-BEAM自体造血干细胞移植。

主要发现

  • 未观察到剂量限制性毒性,推荐2期剂量为0.6 mCi/kg。
  • 毒性反应和植入时间与标准自体造血干细胞移植相似,但95%患者发生口腔炎(均为Bearman毒性量表1-2级)。
  • 观察到7例(32%)复发,多数见于具有≥3个危险因素的患者。
  • 22例可评估患者的估计5年无进展生存率为68%,总生存率为95%,非复发死亡率为0%。

关键数值与推荐

  • 推荐2期剂量为0.6 mCi/kg,该剂量下心脏壁受照剂量不超过2500 cGy。

临床怎么用

  • 对于高危复发难治性霍奇金淋巴瘤患者,aTac-BEAM自体造血干细胞移植预处理是一种耐受性良好的移植平台,与既往霍奇金淋巴瘤治疗无关。

局限性

  • 样本量较小(22例接受治疗),为1期剂量递增试验,疗效需进一步2期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-risk relapsed or refractory (R/R) classical Hodgkin lymphoma (HL) is associated with poor outcomes after conventional salvage therapy and autologous hematopoietic cell transplantation (AHCT). Post-AHCT consolidation with brentuximab vedotin (BV) improves progression-free survival (PFS), but with increasing use of BV early in the treatment course, the utility of consolidation is unclear. CD25 is often expressed on Reed-Sternberg cells and in the tumor microenvironment in HL, and we hypothesized that the addition of 90Y-antiCD25 (aTac) to carmustine, etoposide, cytarabine, melphalan (BEAM) AHCT would be safe and result in a transplantation platform that is agnostic to prior HL-directed therapy. Twenty-five patients with high-risk R/R HL were enrolled in this phase 1 dose-escalation trial of aTac-BEAM. Following an imaging dose of 111In-antiCD25, 2 patients had altered biodistribution, and a third developed an unrelated catheter-associated bacteremia; therefore, 22 patients ultimately received therapeutic 90Y-aTac-BEAM AHCT. No dose-limiting toxicities were observed, and 0.6 mCi/kg was deemed the recommended phase 2 dose, the dose at which the heart wall would not receive >2500 cGy. Toxicities and time to engraftment were similar to those observed with standard AHCT, though 95% of patients developed stomatitis (all grade 1-2 per Bearman toxicity scale). Seven relapses (32%) were observed, most commonly in patients with ≥3 risk factors. The estimated 5-year PFS and overall survival probabilities among 22 evaluable patients were 68% and 95%, respectively, and non-relapse mortality was 0%. aTac-BEAM AHCT was tolerable in patients with high-risk R/R HL, and we are further evaluating the efficacy of this approach in a phase 2 trial. This trial was registered at www.clinicaltrials.gov as #NCT01476839.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Herrera AF, Palmer J, Adhikarla V, et al. Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. Blood Adv. 2021. PMID: 34638132. doi:10.1182/bloodadvances.2021004981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。